Drug Type Synthetic peptide |
Synonyms Octreotide controlled-release, SR Octreotide, PT 201 + [1] |
Target |
Action agonists |
Mechanism SSTR agonists(Somatostatin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC49H66N10O10S2 |
InChIKeyDEQANNDTNATYII-OULOTJBUSA-N |
CAS Registry83150-76-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acromegaly | Phase 2 | - | 30 Apr 2021 | |
Carcinoid Tumor | Phase 2 | - | 30 Apr 2021 |
Phase 3 | Colorectal Cancer Adjuvant | First line | 139 | dahsqtsrzr(gvgzuctntu) = jnxfdesqgl afpeyvhfaz (dxwqxfslxh ) | Negative | 01 Feb 2012 | ||
(Physician's treatment of choice) | dahsqtsrzr(gvgzuctntu) = edmwtzupmn afpeyvhfaz (dxwqxfslxh ) | ||||||
Phase 1/2 | 22 | pzdybehzji(qznimvfdek) = mieiwbebwh lvbjlmcwlw (gekbphdfam ) View more | - | 20 Jun 2007 | |||
pzdybehzji(qznimvfdek) = xlssugvhsf lvbjlmcwlw (gekbphdfam ) View more |